Groupama Asset Managment Purchases Shares of 400,000 Lantheus Holdings, Inc. (NASDAQ:LNTH)

Groupama Asset Managment purchased a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 400,000 shares of the medical equipment provider's stock, valued at approximately $439,000. Groupama Asset Managment owned about 0.58% of Lantheus as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. Farallon Capital Management LLC lifted its holdings in shares of Lantheus by 53.7% during the 2nd quarter. Farallon Capital Management LLC now owns 2,279,227 shares of the medical equipment provider's stock worth $182,999,000 after acquiring an additional 796,000 shares during the period. Point72 Asset Management L.P. bought a new position in Lantheus during the second quarter worth about $26,794,000. Janus Henderson Group PLC boosted its holdings in Lantheus by 7.7% during the third quarter. Janus Henderson Group PLC now owns 3,588,571 shares of the medical equipment provider's stock valued at $393,844,000 after purchasing an additional 257,022 shares in the last quarter. Massachusetts Financial Services Co. MA bought a new stake in shares of Lantheus in the 3rd quarter valued at approximately $25,955,000. Finally, Point72 DIFC Ltd acquired a new position in shares of Lantheus in the 3rd quarter worth approximately $23,001,000. 99.06% of the stock is owned by institutional investors.

Lantheus Stock Down 1.7 %

LNTH stock traded down $1.60 during midday trading on Tuesday, reaching $90.98. The company's stock had a trading volume of 1,090,663 shares, compared to its average volume of 1,015,578. The business's 50-day simple moving average is $98.75 and its 200-day simple moving average is $97.83. The stock has a market cap of $6.33 billion, a PE ratio of 15.14 and a beta of 0.45. Lantheus Holdings, Inc. has a 52 week low of $50.20 and a 52 week high of $126.89.

Wall Street Analysts Forecast Growth

LNTH has been the topic of several analyst reports. Truist Financial reaffirmed a "buy" rating and issued a $120.00 target price (down previously from $135.00) on shares of Lantheus in a report on Friday, November 8th. StockNews.com lowered shares of Lantheus from a "buy" rating to a "hold" rating in a report on Thursday, November 21st. Redburn Atlantic assumed coverage on Lantheus in a report on Tuesday, September 3rd. They issued a "buy" rating and a $175.00 target price on the stock. Finally, JMP Securities decreased their price target on Lantheus from $125.00 to $112.00 and set a "market outperform" rating on the stock in a research report on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $130.00.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.